Trial Profile
ImmunoRad: Stratified Phase II Trial of Image Guided Hypofractionated Radiotherapy With Concurrent Nelfinavir and Immunotherapy in Advanced Melanoma, Lung Cancer, and Renal Cell Carcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 24 Jun 2022
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Nelfinavir (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma
- Focus Therapeutic Use
- 30 Sep 2021 Status changed from recruiting to discontinued due to slow accrual.
- 17 Dec 2020 Planned End Date changed from 1 Dec 2021 to 1 Dec 2024.
- 17 Dec 2020 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2024.